Literature DB >> 15231072

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice.

Lin Tang1, Qingyu Zhu, Ede Qin, Man Yu, Zhifen Ding, Huiying Shi, Xiaojie Cheng, Caiping Wang, Guohui Chang, Qiang Zhu, Fang Fang, Haiyan Chang, Shuangli Li, Xumin Zhang, Xishu Chen, Jun Yu, Jian Wang, Ze Chen.   

Abstract

We tested the ability of inactivated SARS-CoV vaccine to induce neutralizing antibodies in BALB/c mice. The inactivated vaccine was prepared by SARS-CoV virus propagation in Vero cells, with subsequent beta-propiolactone inactivation and Sepharose 4FF column chromatography purification. One hundred forty BALB/c female mice were divided into seven groups of 20 mice each. Of the seven groups, three groups were inoculated with 0.1, 1, and 3 microg of the vaccine without adjuvant while three other groups were inoculated at the same three dosages of vaccine with aluminum hydroxide as adjuvant, respectively. The remaining group was set up as a blank control. Each mouse was inoculated twice at an interval of 3 weeks. One week after the second immunization, mice sera were collected to detect serum neutralizing antibodies. An assay for determining neutralizing antibody titers was developed. The results can be summarized as follows: (1) higher dosages of vaccine induced higher levels of neutralizing antibody titer; (2) the level of neutralizing antibodies induced by the inoculation with aluminum hydroxide adjuvant was slightly higher than that without adjuvant, but the difference was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231072     DOI: 10.1089/104454904323145272

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  48 in total

1.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus.

Authors:  Yuxian He; Yusen Zhou; Pamela Siddiqui; Jinkui Niu; Shibo Jiang
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Authors:  Naoko Iwata-Yoshikawa; Akihiko Uda; Tadaki Suzuki; Yasuko Tsunetsugu-Yokota; Yuko Sato; Shigeru Morikawa; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa; Noriyo Nagata
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 4.  Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.

Authors:  Susan R Weiss; Sonia Navas-Martin
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

5.  A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.

Authors:  Lanying Du; Guangyu Zhao; Chris C S Chan; Lin Li; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

6.  Children's vaccines do not induce cross reactivity against SARS-CoV.

Authors:  Yang Yu; Huali Jin; Ze Chen; Qingling L Yu; Yijie J Ma; Xiaolin L Sun; Bin Wang
Journal:  J Clin Pathol       Date:  2007-02       Impact factor: 3.411

Review 7.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

8.  Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus.

Authors:  Jincun Zhao; Qianrong Huang; Wei Wang; Yan Zhang; Ping Lv; Xiao-Ming Gao
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

9.  Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Authors:  Lanying Du; Guangyu Zhao; Yongping Lin; Hongyan Sui; Chris Chan; Selene Ma; Yuxian He; Shibo Jiang; Changyou Wu; Kwok-Yung Yuen; Dong-Yan Jin; Yusen Zhou; Bo-Jian Zheng
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

10.  Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.

Authors:  Joshua M DiNapoli; Alexander Kotelkin; Lijuan Yang; Subbiah Elankumaran; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.